Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
260,50 € ↑8,70 (3,46%)
2026-06-04
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionAdvisors Asset Management, Inc.
Latest Disclosed Ownership3,952 shares
Latest Disclosed Value $ 1,307,598
Advisors Asset Management, Inc. reports 8.16% decrease in ownership of DUL / Alnylam Pharmaceuticals, Inc.

On May 15, 2026 - Advisors Asset Management, Inc. filed a 13F-HR form disclosing ownership of 3,952 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $1,129,086 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 12, 2026 disclosing 4,303 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of -8.16% during the quarter. The current value of the position is $1,029,496 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,952 -351 -8.16 1,308 -23.61 0.0217
2026-02-12 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,303 -219 -4.84 1,711 -17.02 0.0287
2025-11-06 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,522 -23 -0.51 2,062 39.14 0.0350
2025-08-12 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,545 -1,306 -22.32 1,482 -6.14 0.0265
2025-05-15 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,851 204 3.61 1,580 18.90 0.0297
2025-02-10 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,647 880 18.46 1,329 1.30 0.0245
2024-11-08 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,767 189 4.13 1,311 17.90 0.0241
2024-08-14 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,578 541 13.40 1,112 84.41 0.0217
2024-05-14 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,037 2,664 194.03 603 130.15 0.0116
2024-02-14 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,373 81 6.27 263 14.91 0.0054
2023-11-14 2023-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,292 375 40.89 229 31.03 0.0049
2023-08-14 2023-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 917 -34 -3.58 174 -8.42 0.0036
2023-05-12 2023-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 951 -5 -0.52 191 -16.30 0.0039
2023-02-13 2022-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 956 -1,429 -59.92 227 -52.41 0.0047
2022-11-08 2022-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,385 -469 -16.43 477 14.66 0.0100
2022-08-08 2022-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,854 -1,082 -27.49 416 -35.30 0.0079
2022-05-17 2022-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,936 292 8.01 643 4.05 0.0099
2022-02-15 2021-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,644 -49 -1.33 618 -11.33 0.0088
2021-11-12 2021-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,693 8 0.22 697 11.52 0.0106
2021-07-30 2021-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,685 -1,232 -25.06 625 -9.94 0.0092
2021-05-07 2021-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,917 379 8.35 694 17.63 0.0108
2021-02-12 2020-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,538 688 17.87 590 5.17 0.0098
2020-11-16 2020-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,850 -575 -12.99 561 -14.35 0.0104
2020-08-12 2020-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,425 -689 -13.47 655 17.59 0.0128
2020-05-15 2020-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,114 -2,927 -36.40 557 -39.85 0.0133
2020-05-20 2019-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 8,041 1,447 21.94 926 74.72 0.0162
2020-02-14 2019-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 8,041 1,447 926 8,195.9755
2019-11-14 2019-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 6,594 -7,448 -53.04 530 -47.99 0.0098
2019-11-14 2019-06-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 14,042 -3,622 -20.50 1,019 -38.28 0.0184
2019-08-14 2019-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 14,042 -3,622 1,019
2019-05-15 2019-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 17,664 -219 -1.22 1,651 26.61 0.0294
2019-02-06 2018-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 17,883 155 0.87 1,304 -15.98 0.0263
2019-01-31 2018-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 17,883 155 1,304
2018-11-15 2018-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 17,728 727 4.28 1,552 -7.29 0.0254
2018-08-22 2018-06-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 17,001 2,298 15.63 1,674 -5.26 0.0284
2018-08-15 2018-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 54,368 39,665 1,674
2018-05-15 2018-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 14,703 726 5.19 1,767 -0.51 0.0296
2018-02-13 2017-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 13,977 1,025 7.91 1,776 16.69 0.0292
2017-11-07 2017-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 12,952 4,332 50.26 1,522 121.22 0.0255
2017-08-02 2017-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 8,620 -875 -9.22 688 41.27 0.0115
2017-05-02 2017-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 9,495 -16,731 -63.80 487 -72.61 0.0082
2016-10-31 2016-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 26,226 -21,893 -45.50 1,778 -33.41 0.0292
2016-08-08 2016-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 48,119 -4,806 -9.08 2,670 -19.63 0.0433
2016-05-16 2016-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 52,925 -11,902 -18.36 3,322 -45.57 0.0553
2016-02-10 2015-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 64,827 226 0.35 6,103 17.57 0.0968
2015-11-16 2015-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 64,601 9,681 17.63 5,191 -21.15 0.0828
2015-08-11 2015-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 54,920 8,250 17.68 6,583 35.09 0.0903
2015-05-13 2015-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 46,670 13,912 42.47 4,873 53.34 0.0649
2015-02-05 2014-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 32,758 9,676 41.92 3,178 76.26 0.0426
2014-11-13 2014-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 23,082 10,166 78.71 1,803 120.96 0.0249
2014-08-14 2014-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 12,916 7,968 161.03 816 145.78 0.0113
2014-05-15 2014-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,948 4,948 332 0.0050
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.